FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221075808> ?p ?o ?g. }

• W4221075808 endingPage "57" @default.
• W4221075808 startingPage "45" @default.
• W4221075808 abstract "Acral melanoma is a predominant and aggressive subtype of melanoma in non-Caucasian populations. There is a lack of genotype-driven therapies for over 50% of patients. TRPM1 (transient receptor potential melastatin 1), a nonspecific cation channel, is mainly expressed in retinal bipolar neurons and skin. Nonetheless, the function of TRPM1 in melanoma progression is poorly understood.We investigated the association between TRPM1 and acral melanoma progression and revealed the molecular mechanisms by which TRPM1 promotes tumor progression and malignancy.TRPM1 expression and CaMKII phosphorylation in tumor specimens were tested by immunohistochemistry analysis and scored by two independent investigators. The functions of TRPM1 and CaMKII were assessed using loss-of-function and gain-of-function approaches and examined by western blotting, colony formation, cell migration and invasion, and xenograft tumor growth assays. The effects of a CaMKII inhibitor, KN93, were evaluated using both in vitro cell and in vivo xenograft mouse models.We revealed that TRPM1 protein expression was positively associated with tumor progression and shorter survival in patients with acral melanoma. TRPM1 promoted AKT activation and the colony formation, cell mobility, and xenograft tumor growth of melanoma cells. TRPM1 elevated cytosolic Ca2+ levels and activated CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) to promote the CaMKIIδ/AKT interaction and AKT activation. The functions of TRPM1 in melanoma cells were suppressed by a CaMKII inhibitor, KN93. Significant upregulation of phospho-CaMKII levels in acral melanomas was related to increased expression of TRPM1. An acral melanoma cell line with high expression of TRPM1, CA11, was isolated from a patient to show the anti-tumor activity of KN93 in vitro and in vivo.TRPM1 promotes tumor progression and malignancy in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway. CaMKII inhibition may be a potential therapeutic strategy for treating acral melanomas with high expression of TRPM1." @default.
• W4221075808 created "2022-04-03" @default.
• W4221075808 creator A5018333718 @default.
• W4221075808 creator A5018953595 @default.
• W4221075808 creator A5019757415 @default.
• W4221075808 creator A5027997159 @default.
• W4221075808 creator A5042435674 @default.
• W4221075808 creator A5047178782 @default.
• W4221075808 creator A5050697930 @default.
• W4221075808 creator A5056119901 @default.
• W4221075808 creator A5067694769 @default.
• W4221075808 creator A5085668246 @default.
• W4221075808 date "2023-01-01" @default.
• W4221075808 modified "2023-09-26" @default.
• W4221075808 title "TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway" @default.
• W4221075808 cites W1552222951 @default.
• W4221075808 cites W1887671912 @default.
• W4221075808 cites W1950829641 @default.
• W4221075808 cites W1968669063 @default.
• W4221075808 cites W1972479538 @default.
• W4221075808 cites W1973268693 @default.
• W4221075808 cites W2001256555 @default.
• W4221075808 cites W2007190649 @default.
• W4221075808 cites W2023853595 @default.
• W4221075808 cites W2028449729 @default.
• W4221075808 cites W2033182545 @default.
• W4221075808 cites W2039861849 @default.
• W4221075808 cites W2040008189 @default.
• W4221075808 cites W2044132837 @default.
• W4221075808 cites W2049467066 @default.
• W4221075808 cites W2051882611 @default.
• W4221075808 cites W2053583111 @default.
• W4221075808 cites W2066437531 @default.
• W4221075808 cites W2070776182 @default.
• W4221075808 cites W2075726466 @default.
• W4221075808 cites W2081614214 @default.
• W4221075808 cites W2094910328 @default.
• W4221075808 cites W2107513374 @default.
• W4221075808 cites W2124662474 @default.
• W4221075808 cites W2138231889 @default.
• W4221075808 cites W2151432329 @default.
• W4221075808 cites W2163978292 @default.
• W4221075808 cites W2268786083 @default.
• W4221075808 cites W2340761255 @default.
• W4221075808 cites W2346267653 @default.
• W4221075808 cites W2363557629 @default.
• W4221075808 cites W2510050774 @default.
• W4221075808 cites W2605233023 @default.
• W4221075808 cites W2611187032 @default.
• W4221075808 cites W2624937154 @default.
• W4221075808 cites W2725858897 @default.
• W4221075808 cites W2755158403 @default.
• W4221075808 cites W2755173869 @default.
• W4221075808 cites W2902153433 @default.
• W4221075808 cites W2908644623 @default.
• W4221075808 cites W2914786206 @default.
• W4221075808 cites W3004493255 @default.
• W4221075808 cites W3010542623 @default.
• W4221075808 cites W3012909157 @default.
• W4221075808 cites W3032523770 @default.
• W4221075808 cites W3092852290 @default.
• W4221075808 cites W3108395535 @default.
• W4221075808 cites W3121362923 @default.
• W4221075808 cites W3185442213 @default.
• W4221075808 cites W4252241660 @default.
• W4221075808 cites W4384261515 @default.
• W4221075808 doi "https://doi.org/10.1016/j.jare.2022.03.005" @default.
• W4221075808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585114" @default.
• W4221075808 hasPublicationYear "2023" @default.
• W4221075808 type Work @default.
• W4221075808 citedByCount "3" @default.
• W4221075808 countsByYear W42210758082023 @default.
• W4221075808 crossrefType "journal-article" @default.
• W4221075808 hasAuthorship W4221075808A5018333718 @default.
• W4221075808 hasAuthorship W4221075808A5018953595 @default.
• W4221075808 hasAuthorship W4221075808A5019757415 @default.
• W4221075808 hasAuthorship W4221075808A5027997159 @default.
• W4221075808 hasAuthorship W4221075808A5042435674 @default.
• W4221075808 hasAuthorship W4221075808A5047178782 @default.
• W4221075808 hasAuthorship W4221075808A5050697930 @default.
• W4221075808 hasAuthorship W4221075808A5056119901 @default.
• W4221075808 hasAuthorship W4221075808A5067694769 @default.
• W4221075808 hasAuthorship W4221075808A5085668246 @default.
• W4221075808 hasBestOaLocation W42210758081 @default.
• W4221075808 hasConcept C11960822 @default.
• W4221075808 hasConcept C121608353 @default.
• W4221075808 hasConcept C2777658100 @default.
• W4221075808 hasConcept C2779256057 @default.
• W4221075808 hasConcept C502942594 @default.
• W4221075808 hasConcept C54355233 @default.
• W4221075808 hasConcept C75217442 @default.
• W4221075808 hasConcept C86803240 @default.
• W4221075808 hasConcept C95444343 @default.
• W4221075808 hasConceptScore W4221075808C11960822 @default.
• W4221075808 hasConceptScore W4221075808C121608353 @default.
• W4221075808 hasConceptScore W4221075808C2777658100 @default.
• W4221075808 hasConceptScore W4221075808C2779256057 @default.
• W4221075808 hasConceptScore W4221075808C502942594 @default.

• next